Table I.
Baseline Treatments According to the Presence of the Metabolic Syndrome (MS)
Treatments | Overall (n=642; 100%) | MS (n=171; 26.7%) | No MS (n=471; 73.3%) | P Value |
---|---|---|---|---|
Antiplatelets, % | 97.2 | 96.4 | 97.5 | Not significant |
Anticoagulants, % | 9.0 | 11.2 | 8.3 | <.05 |
β‐Blockers, % | 74.5 | 72.6 | 75.1 | Not significant |
Angiotensin‐renin system inhibitor, % | 51.7 | 45.3 | 54.1 | <.05 |
Lipid‐lowering drugs, % | 99.7 | 100 | 99.6 | Not significant |
Antidiabetics, % | 11.7 | 21.7 | 7.4 | <.05 |